{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:48:13Z","timestamp":1707526093912},"reference-count":43,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,8]]},"DOI":"10.7759\/cureus.53851","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T16:40:59Z","timestamp":1707410459000},"source":"Crossref","is-referenced-by-count":0,"title":["Advanced and Metastatic Gastrointestinal Stromal Tumors Presenting With Surgical Emergencies Managed With Surgical Resection: A Case Series"],"prefix":"10.7759","author":[{"given":"Divij","family":"Jayant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mrinal","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swapnesh","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basil","family":"Babu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satish","family":"Subbiah Nagaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cherring","family":"Tandup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arunanshu","family":"Behera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60106-3","article-title":"Gastrointestinal stromal tumour","volume":"382","author":"Joensuu H","year":"2013","unstructured":"Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013, 382:973-83. 10.1016\/S0140-6736(13)60106-3","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-0074-y","article-title":"Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs","volume":"29","author":"Emile JF","year":"2012","unstructured":"Emile JF, Brahimi S, Coindre JM, et al.. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol. 2012, 29:1765-72. 10.1007\/s12032-011-0074-y","journal-title":"Med Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.09.009","article-title":"Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study","volume":"41","author":"Goettsch WG","year":"2005","unstructured":"Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005, 41:2868-72. 10.1016\/j.ejca.2005.09.009","journal-title":"Eur J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63279-8","article-title":"The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status","volume":"165","author":"West RB","year":"2004","unstructured":"West RB, Corless CL, Chen X, et al.. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004, 165:107-13. 10.1016\/S0002-9440(10)63279-8","journal-title":"Am J Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4970","article-title":"KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence","volume":"33","author":"Joensuu H","year":"2015","unstructured":"Joensuu H, Rutkowski P, Nishida T, et al.. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. J Clin Oncol. 2015, 33:634-42. 10.1200\/JCO.2014.57.4970","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60500-6","article-title":"Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"Dematteo RP","year":"2009","unstructured":"Dematteo RP, Ballman KV, Antonescu CR, et al.. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009, 373:1097-104. 10.1016\/S0140-6736(09)60500-6","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00836-5","article-title":"Imatinib mesylate (STI-571 Glivec\u00ae, Gleevec\u2122) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study","volume":"39","author":"Verweij J","year":"2003","unstructured":"Verweij J, van Oosterom A, Blay JY, et al.. Imatinib mesylate (STI-571 Glivec\u00ae, Gleevec\u2122) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer. 2003, 39:2006-11. 10.1016\/S0959-8049(02)00836-5","journal-title":"Eur J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.2046","article-title":"Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial","volume":"32","author":"Corless CL","year":"2014","unstructured":"Corless CL, Ballman KV, Antonescu CR, et al.. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol. 2014, 32:1563-70. 10.1200\/JCO.2013.51.2046","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4304","article-title":"Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European organisation for research and treatment of cancer soft tissue and bone sarcoma group intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish group for research on sarcomas","volume":"33","author":"Casali PG","year":"2015","unstructured":"Casali PG, Le Cesne A, Poveda Velasco A, et al.. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European organisation for research and treatment of cancer soft tissue and bone sarcoma group intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish group for research on sarcomas. J Clin Oncol. 2015, 33:4276-83. 10.1200\/JCO.2015.62.4304","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2018.10.031","article-title":"The PROCESS 2018 statement: updating consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) guidelines","volume":"60","author":"Agha RA","year":"2018","unstructured":"Agha RA, Borrelli MR, Farwana R, Koshy K, Fowler AJ, Orgill DP. The PROCESS 2018 statement: updating consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) guidelines. Int J Surg. 2018, 60:279-82. 10.1016\/j.ijsu.2018.10.031","journal-title":"Int J Surg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21419","article-title":"Gastrointestinal stromal tumor: 5 years later","volume":"104","author":"van der Zwan SM","year":"2005","unstructured":"van der Zwan SM, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer. 2005, 104:1781-8. 10.1002\/cncr.21419","journal-title":"Cancer"},{"key":"ref12","article-title":"Soft tissue and bone tumours: WHO classification of tumours, 5th edition, volume 3","author":"WHO Classification of Tumours Editorial Board","year":"2020","unstructured":"WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours: WHO classification of tumours, 5th edition, volume 3. IARC Press, Lyon, France; 2020."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2009.02110.x","article-title":"The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications","volume":"266","author":"Stratakis CA","year":"2009","unstructured":"Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med. 2009, 266:43-52. 10.1111\/j.1365-2796.2009.02110.x","journal-title":"J Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0256","article-title":"Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health gastrointestinal stromal tumor clinic","volume":"2","author":"Boikos SA","year":"2016","unstructured":"Boikos SA, Pappo AS, Killian JK, et al.. Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health gastrointestinal stromal tumor clinic. JAMA Oncol. 2016, 2:922-8. 10.1001\/jamaoncol.2016.0256","journal-title":"JAMA Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s004280000338","article-title":"Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis","volume":"438","author":"Miettinen M","year":"2001","unstructured":"Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001, 438:1-12. 10.1007\/s004280000338","journal-title":"Virchows Arch"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1148\/rg.232025146","article-title":"Gastrointestinal stromal tumors: radiologic features with pathologic correlation","volume":"23","author":"Levy AD","year":"2003","unstructured":"Levy AD, Remotti HE, Thompson WM, Sobin LH, Miettinen M. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics. 2003, 23:283-304, 456; quiz 532. 10.1148\/rg.232025146","journal-title":"Radiographics"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2013.09.002","article-title":"MDCT of primary, locally recurrent, and metastatic duodenal gastrointestinal stromal tumours (GISTs): a single institution study of 25 patients with review of literature","volume":"69","author":"Cheng JM","year":"2014","unstructured":"Cheng JM, Tirumani SH, Shinagare AB, Jagannathan JP, Hornick JL, Raut CP, Ramaiya NH. MDCT of primary, locally recurrent, and metastatic duodenal gastrointestinal stromal tumours (GISTs): a single institution study of 25 patients with review of literature. Clin Radiol. 2014, 69:137-44. 10.1016\/j.crad.2013.09.002","journal-title":"Clin Radiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181c20f4f","article-title":"Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases","volume":"34","author":"Zhang L","year":"2010","unstructured":"Zhang L, Smyrk TC, Young WF Jr, Stratakis CA, Carney JA. Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol. 2010, 34:53-64. 10.1097\/PAS.0b013e3181c20f4f","journal-title":"Am J Surg Pathol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5858\/2006-130-1466-GSTROM","article-title":"Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis","volume":"130","author":"Miettinen M","year":"2006","unstructured":"Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006, 130:1466-78. 10.5858\/2006-130-1466-GSTROM","journal-title":"Arch Pathol Lab Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.246","article-title":"ACG clinical guideline: diagnosis and management of small bowel bleeding","volume":"110","author":"Gerson LB","year":"2015","unstructured":"Gerson LB, Fidler JL, Cave DR, Leighton JA. ACG clinical guideline: diagnosis and management of small bowel bleeding. Am J Gastroenterol. 2015, 110:1265-87; quiz 1288. 10.1038\/ajg.2015.246","journal-title":"Am J Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1148\/rg.262055097","article-title":"Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib","volume":"26","author":"Hong X","year":"2006","unstructured":"Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics. 2006, 26:481-95. 10.1148\/rg.262055097","journal-title":"Radiographics"},{"key":"ref22","article-title":"Current endoscopic ultrasound-guided approach to incidental subepithelial lesions: optimal or optional?","volume":"28","author":"Eckardt AJ","year":"2015","unstructured":"Eckardt AJ, Jenssen C. Current endoscopic ultrasound-guided approach to incidental subepithelial lesions: optimal or optional?. Ann Gastroenterol. 2015, 28:160-72.","journal-title":"Ann Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/gut.46.1.88","article-title":"Endosonographic features predictive of benign and malignant gastrointestinal stromal cell tumours","volume":"46","author":"Palazzo L","year":"2000","unstructured":"Palazzo L, Landi B, Cellier C, Cuillerier E, Roseau G, Barbier JP. Endosonographic features predictive of benign and malignant gastrointestinal stromal cell tumours. Gut. 2000, 46:88-92. 10.1136\/gut.46.1.88","journal-title":"Gut"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.13-S2-8","article-title":"The lessons of GIST--PET and PET\/CT: a new paradigm for imaging","volume":"13 Suppl 2","author":"Van den Abbeele AD","year":"2008","unstructured":"Van den Abbeele AD. The lessons of GIST--PET and PET\/CT: a new paradigm for imaging. Oncologist. 2008, 13 Suppl 2:8-13. 10.1634\/theoncologist.13-S2-8","journal-title":"Oncologist"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70299-6","article-title":"Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts","volume":"13","author":"Joensuu H","year":"2012","unstructured":"Joensuu H, Vehtari A, Riihim\u00e4ki J, et al.. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012, 13:265-74. 10.1016\/S1470-2045(11)70299-6","journal-title":"Lancet Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy095","article-title":"Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali PG","year":"2018","unstructured":"Casali PG, Abecassis N, Aro HT, et al.. Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018, 29:iv68-78. 10.1093\/annonc\/mdy095","journal-title":"Ann Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.3439","article-title":"Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors","volume":"24","author":"Raut CP","year":"2006","unstructured":"Raut CP, Posner M, Desai J, et al.. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006, 24:2325-31. 10.1200\/JCO.2005.05.3439","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000236630.93587.59","article-title":"Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor","volume":"245","author":"DeMatteo RP","year":"2007","unstructured":"DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007, 245:347-52. 10.1097\/01.sla.0000236630.93587.59","journal-title":"Ann Surg"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199201000-00010","article-title":"Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging","volume":"215","author":"Ng EH","year":"1992","unstructured":"Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg. 1992, 215:68-77. 10.1097\/00000658-199201000-00010","journal-title":"Ann Surg"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60780-6","article-title":"Gastrointestinal stromal tumour","volume":"369","author":"Rubin BP","year":"2007","unstructured":"Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007, 369:1731-41. 10.1016\/S0140-6736(07)60780-6","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000218080.94145.cf","article-title":"Combined surgical and molecular therapy: the gastrointestinal stromal tumor model","volume":"244","author":"Gold JS","year":"2006","unstructured":"Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg. 2006, 244:176-84. 10.1097\/01.sla.0000218080.94145.cf","journal-title":"Ann Surg"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00254-5","article-title":"Gastrointestinal stromal tumours","volume":"7","author":"Blay JY","year":"2021","unstructured":"Blay JY, Kang YK, Nishida T, von Mehren M. Gastrointestinal stromal tumours. Nat Rev Dis Primers. 2021, 7:22. 10.1038\/s41572-021-00254-5","journal-title":"Nat Rev Dis Primers"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-72","article-title":"Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial","volume":"11","author":"Blesius A","year":"2011","unstructured":"Blesius A, Cassier PA, Bertucci F, et al.. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer. 2011, 11:72. 10.1186\/1471-2407-11-72","journal-title":"BMC Cancer"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2012.09.004","article-title":"Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib","volume":"39","author":"Tielen R","year":"2013","unstructured":"Tielen R, Verhoef C, van Coevorden F, et al.. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. Eur J Surg Oncol. 2013, 39:150-5. 10.1016\/j.ejso.2012.09.004","journal-title":"Eur J Surg Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ciresp.2008.09.023","article-title":"[Surgical treatment of an advanced GIST the age of imatinib]","volume":"86","author":"Fern\u00e1ndez JA","year":"2009","unstructured":"Fern\u00e1ndez JA, Parrilla P. [Surgical treatment of an advanced GIST the age of imatinib]. Cir Esp. 2009, 86:3-12. 10.1016\/j.ciresp.2008.09.023","journal-title":"Cir Esp"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001014","article-title":"Feasibility and timing of cytoreduction surgery in advanced (metastatic or recurrent) gastrointestinal stromal tumors during the era of imatinib","volume":"94","author":"Chang SC","year":"2015","unstructured":"Chang SC, Liao CH, Wang SY, et al.. Feasibility and timing of cytoreduction surgery in advanced (metastatic or recurrent) gastrointestinal stromal tumors during the era of imatinib. Medicine (Baltimore). 2015, 94:e1014. 10.1097\/MD.0000000000001014","journal-title":"Medicine (Baltimore)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2016.05.006","article-title":"Combined therapy of gastrointestinal stromal tumors","volume":"25","author":"Rutkowski P","year":"2016","unstructured":"Rutkowski P, Hompes D. Combined therapy of gastrointestinal stromal tumors. Surg Oncol Clin N Am. 2016, 25:735-59. 10.1016\/j.soc.2016.05.006","journal-title":"Surg Oncol Clin N Am"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21160","article-title":"Phase II trial of neoadjuvant\/adjuvant imatinib mesylate (IM) for advanced primary and metastatic\/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132\/ACRIN 6665","volume":"99","author":"Eisenberg BL","year":"2009","unstructured":"Eisenberg BL, Harris J, Blanke CD, et al.. Phase II trial of neoadjuvant\/adjuvant imatinib mesylate (IM) for advanced primary and metastatic\/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132\/ACRIN 6665. J Surg Oncol. 2009, 99:42-7. 10.1002\/jso.21160","journal-title":"J Surg Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.4403","article-title":"Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT","volume":"26","author":"Blanke CD","year":"2008","unstructured":"Blanke CD, Demetri GD, von Mehren M, et al.. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008, 26:620-5. 10.1200\/JCO.2007.13.4403","journal-title":"J Clin Oncol"},{"key":"ref40","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Soft tissue sarcoma. (2019). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma.pdf."},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.21037\/tgh.2018.02.02","article-title":"Surgery for metastatic gastrointestinal stromal tumor: to whom and how to?","volume":"3","author":"Kikuchi H","year":"2018","unstructured":"Kikuchi H, Hiramatsu Y, Kamiya K, Morita Y, Sakaguchi T, Konno H, Takeuchi H. Surgery for metastatic gastrointestinal stromal tumor: to whom and how to?. Transl Gastroenterol Hepatol. 2018, 3:14. 10.21037\/tgh.2018.02.02","journal-title":"Transl Gastroenterol Hepatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.02.004","article-title":"Gastrointestinal stromal tumors (GIST) related emergencies","volume":"12","author":"Sorour MA","year":"2014","unstructured":"Sorour MA, Kassem MI, Ghazal Ael-H, El-Riwini MT, Abu Nasr A. Gastrointestinal stromal tumors (GIST) related emergencies. Int J Surg. 2014, 12:269-80. 10.1016\/j.ijsu.2014.02.004","journal-title":"Int J Surg"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-015-1282-4","article-title":"Primary surgery as a frontline treatment for synchronous metastatic gastrointestinal stromal tumors: an analysis of the Kinki GIST registry","volume":"46","author":"Sato S","year":"2016","unstructured":"Sato S, Tsujinaka T, Yamamoto K, et al.. Primary surgery as a frontline treatment for synchronous metastatic gastrointestinal stromal tumors: an analysis of the Kinki GIST registry. Surg Today. 2016, 46:1068-75. 10.1007\/s00595-015-1282-4","journal-title":"Surg Today"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/222294-advanced-and-metastatic-gastrointestinal-stromal-tumors-presenting-with-surgical-emergencies-managed-with-surgical-resection-a-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:18:57Z","timestamp":1707506337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/222294-advanced-and-metastatic-gastrointestinal-stromal-tumors-presenting-with-surgical-emergencies-managed-with-surgical-resection-a-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":43,"URL":"https:\/\/doi.org\/10.7759\/cureus.53851","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,8]]}}}